Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price target on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Up 0.1 %

NASDAQ:NERV opened at $2.82 on Monday. The stock has a market capitalization of $19.72 million, a price-to-earnings ratio of -0.63 and a beta of 0.14. Minerva Neurosciences has a 52 week low of $2.26 and a 52 week high of $13.49. The firm has a 50 day moving average of $2.88 and a 200 day moving average of $2.80.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, analysts expect that Minerva Neurosciences will post -2.26 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.